a 62176 has been researched along with cyclin d1 in 1 studies
| Studies (a 62176) | Trials (a 62176) | Recent Studies (post-2010) (a 62176) | Studies (cyclin d1) | Trials (cyclin d1) | Recent Studies (post-2010) (cyclin d1) |
|---|---|---|---|---|---|
| 6 | 0 | 1 | 10,885 | 70 | 5,157 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, Y; Jeon, KH; Jun, KY; Kim, DK; Kim, HL; Kwon, Y; Na, Y | 1 |
1 other study(ies) available for a 62176 and cyclin d1
| Article | Year |
|---|---|
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Topics: Antigens, Neoplasm; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Doxorubicin; G1 Phase; HEK293 Cells; Humans; Mediator Complex; Mitogen-Activated Protein Kinase Kinases; Oxazines; Phosphorylation; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ets; Quinolones; Receptor, ErbB-2; Signal Transduction; Stomach Neoplasms; Topoisomerase Inhibitors; Transcription Factors; Up-Regulation | 2012 |